The Therapeutic Effects of Goreisan, a Traditional Japanese Herbal Medicine, on Lower-Limb Lymphedema after Lymphadenectomy in Gynecologic Malignancies: A Case Series Study
Table 2
Pre and posttreatment status of LLL stratified by the CDT group and CDT-G group.
Total population (n = 19)
CDT group (n = 8)
CDT-G group (n = 11)
value
Pretreatment status
BMI (kg/m2) (mean, 95% CI)
22.59 (20.59–24.59)
23.31 (20.17–26.47)
22.08 (19.39–24.76)
0.5346
Body mass (kg) (mean, 95% CI)
55.90 (50.76–61.04)
57.55 (49.44–65.67)
54.71 (47.79–61.63)
0.5814
ECW/TBW (mean, 95% CI)
Total body
0.396 (0.390–0.401)
0.392 (0.384–0.400)
0.398 (0.392–0.405)
0.2292
Affected lower limb
0.404 (0.394–0.413)
0.399 (0.384–0.413)
0.407 (0.395–0.419)
0.34
Unaffected lower limb
0.394 (0.390–0.399)
0.391 (0.384–0.398)
0.397 (0.391–0.403)
0.2072
Estimated volume (mL) (mean, 95% CI)
Affected lower limb
7134.54 (6235.6–8033.5)
7529.88 (6123.2–8936.5)
6847.02 (5647.4–8046.6)
0.4465
Unaffected lower limb
6454.25 (5760.5–7148.0)
6818.64 (5741.3–7896.0)
6189.24 (5270.5–7108.0)
0.3614
Posttreatment status
BMI (kg/m2) (mean, 95% CI)
22.36 (20.33–24.39)
23.51 (20.37–26.65)
21.53 (18.85–24.21)
0.3253
Body mass (kg) (mean, 95% CI)
55.27 (50.26–60.29)
58.01 (50.28–65.78)
53.29 (46.67–59.91)
0.3427
ECW/TBW (mean, 95% CI)
Total body
0.393 (0.388–0.397)
0.392 (0.385–0.399)
0.393 (0.387–0.399)
0.8366
Affected lower limb
0.400 (0.392–0.408)
0.399 (0.387–0.412)
0.400 (0.390–0.411)
0.8976
Unaffected lower limb
0.392 (0.387–0.396)
0.391 (0.384–0.398)
0.392 (0.386–0.399)
0.733
Estimated volume (mL) (mean, 95% CI)
Affected lower limb
7150.27 (6210.2–8090.3)
7671.53 (6216.1–9127.0)
6771.18 (5530.0–8012.4)
0.3346
Unaffected lower limb
6390.62 (5746.5–7034.8)
6688.24 (5682.1–7694.3)
6174.17 (5316.2–7032.2)
0.4234
LLL, lower-limb lymphedema; CDT, complex decongestive therapy; CDT-G, combination of complex decongestive therapy and goreisan; BMI, body mass index; CI, confidence interval; ECW/TBW, ratio of extracellular water to total body water.
